Medtronic, Inc.

Video: Medtronic Partners with Patient Advocacy Groups to Launch Educational Campaign During Bladder Health Awareness Month [Press Release]
PRNewswire | 3 days 8 hours 24 minutes ago
... MINNEAPOLIS, Nov. 20 /PRNewswire/ -- Medtronic, Inc. today announced the kick-off of an educational...and in turn, take control of their bodies. Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the...

Medtronic Introduces 3D Recon Service to Enhance Endovascular Treatment of Aortic Aneurysms [Press Release]
Business Wire | 4 days 23 hours 32 minutes ago
Continuing to drive innovation in endovascular aortic repair (EVAR), Medtronic, Inc. (NYSE: MDT), today announced the introduction of an imaging and visualization service for endovascular specialists who use the company’s market-leading portfolio of stent grafts to treat aortic aneurysms. Aortic aneurysms affect more than one million people in the United States alone and can rupture with fatal consequences if left untreated.

Medtronic Announces the Grand Opening of Its New Diabetes Center in San Antonio [Press Release]
Business Wire | 6 days 20 hours 2 minutes ago
Medtronic, Inc. (NYSE:MDT) today announced the grand opening of its new Diabetes Therapy Management and Education Center in San Antonio. The new operation provides customer care and education for patients and healthcare professionals using Medtronic insulin pumps, continuous glucose monitoring and therapy management software for the treatment of diabetes.

Statement by Medtronic Chairman and CEO Bill Hawkins Regarding U.S. Senate's Revised Medical Device Industry Fee Proposal [Press Release]
Business Wire | 4 days 16 hours 26 minutes ago
Medtronic, Inc. (NYSE: MDT), chairman and CEO Bill Hawkins today issued the following statement regarding the U.S. Senate’s revised proposal regarding a medical device industry fee released yesterday. This new proposal amends the Senate Finance Committee’s earlier proposed $40 billion fee on the medical device industry.

Medtronic Chairman and CEO Bill Hawkins Provides Statement on U.S. Senate s Revised Medical Device Industry Fee Proposal [Press Release]
Business Wire | 4 days 16 hours 20 minutes ago
Medtronic, Inc. (NYSE: MDT), chairman and CEO Bill Hawkins today issued the following statement regarding the U.S. Senate’s revised proposal regarding a medical device industry fee released yesterday. This new proposal amends the Senate Finance Committee’s earlier proposed $40 billion fee on the medical device industry.

Medtronic Chairman and CEO Bill Hawkins Comments on U.S. Senate's Revised Medical Device Industry Fee Proposal [Press Release]
Business Wire | 4 days 16 hours 24 minutes ago
Medtronic, Inc. (NYSE: MDT), chairman and CEO Bill Hawkins today issued the following statement regarding the U.S. Senate’s revised proposal regarding a medical device industry fee released yesterday. This new proposal amends the Senate Finance Committee’s earlier proposed $40 billion fee on the medical device industry.

Medtronic Receives International Business Leadership Award from the Greater Miami Chamber of Commerce [Press Release]
Business Wire | 4 days 16 hours 24 minutes ago
Medtronic, Inc. received today an International Business Leadership Award from the Greater Miami Chamber of Commerce in recognition for its significant impact on the economy of the state of Florida in the Education & Training category.

Medtronic Launches the TSRH 3Dx Spinal System [Press Release]
Business Wire | 6 days 17 hours 42 minutes ago
Medtronic, Inc. (NYSE: MDT), today announced the launch of the TSRH® 3Dx™ Spinal System. Designed with procedural efficiency in mind, the TSRH 3Dx Spinal System offers two screws designed to address multiple pathologies. The Multi Planar Adjusting (MPA®) Screw option provides surgeons a variable angle posted screw for targeted, controlled correction maneuvers. The OSTEOGRIP® Screw enhances bone fixation by incorporating a dual-lead thread pattern that reduces toggle at the bone-screw interface.

Medtronic Launches Global Clinical Trial Evaluating Outcomes from Comprehensive Attain Family of Left Heart Leads and Delivery Catheters [Press Release]
Business Wire | 13 days 21 hours 31 minutes ago
Medtronic, Inc. (NYSE: MDT) today announced the first enrollment in the global Attain Success trial that will evaluate implant success, complication rates and procedure times in the market-released Attain® Family of left-heart leads and delivery systems portfolio. Fifteen new Attain Family therapy delivery products were commercially released in the last two years, including 13 catheters and two Medtronic-exclusive left-heart leads – Attain StarFix® and Attain Ability®. Safwat Gassis, M.D. wit...

Medtronic Receives FDA Warning Letter Following Inspection of Its Mounds View, Minn. Facility [Press Release]
Business Wire | 5 days 21 hours 34 minutes ago
Medtronic (NYSE: MDT) today announced it received a warning letter from the U.S. Food and Drug Administration (FDA) regarding the inspection of the Company’s Mounds View, Minn. (Cardiac Rhythm Disease Management) facility completed in August 2009.

Recent Studies Suggest Benefits of Continuous Glucose Monitoring [Press Release]
MarketWire | 10 days 15 hours 32 minutes ago
BRAMPTON, ONTARIO -- (Marketwire) -- 11/13/09 -- Editors Note: There is a photo available with this Press Release

Medtronic to Announce Financial Results for Its Second Fiscal Quarter [Press Release]
Business Wire | 13 days 14 hours 2 minutes ago
Medtronic, Inc. (NYSE: MDT), announced today it will report financial results for its second fiscal quarter on Tuesday, Nov. 24, 2009. A news release will be issued at approximately 6:15 a.m. Central Time and will be available at www.medtronic.com/newsroom. The earnings news release will include summary financial information for Medtronic’s second quarter ended Oct. 30, 2009.

Medtronic Starts Study of Interventional Erectile Dysfunction Therapy [Press Release]
Business Wire | 41 days 17 hours 32 minutes ago
Medtronic, Inc. (NYSE: MDT), announced today the initiation of a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent system. The study, called ZEN (Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males with Sub-Optimal Response to PDE5 Inhibitors), is being performed under an investigational device exemption (IDE) issued by the U.S. Food and Drug Administration and is expected...